CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin
- 1 October 2018
- journal article
- research article
- Published by Elsevier in European Journal of Radiology
- Vol. 107, 175-182
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyAnnals of Oncology, 2012
- Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different SchedulesJournal of Clinical Oncology, 2009
- The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with TrabectedinMarine Drugs, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response CriteriaJournal of Clinical Oncology, 2007
- Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group TrialJournal of Clinical Oncology, 2005
- Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to ChemotherapyJournal of Clinical Oncology, 2004
- Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma PatientsJournal of Clinical Oncology, 2004
- New agents in cancer clinical trialsOncogene, 2000